Wall Street brokerages predict that Aimmune Therapeutics Inc (NASDAQ:AIMT) will report earnings per share (EPS) of ($0.83) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aimmune Therapeutics’ earnings, with estimates ranging from ($0.95) to ($0.76). Aimmune Therapeutics posted earnings per share of ($0.63) during the same quarter last year, which would suggest a negative year-over-year growth rate of 31.7%. The company is scheduled to issue its next earnings results on Monday, November 5th.
According to Zacks, analysts expect that Aimmune Therapeutics will report full year earnings of ($3.63) per share for the current year, with EPS estimates ranging from ($4.14) to ($3.31). For the next year, analysts expect that the company will post earnings of ($3.23) per share, with EPS estimates ranging from ($3.60) to ($2.72). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Aimmune Therapeutics.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.05).
A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 22nd. Wedbush reissued an “outperform” rating and issued a $72.00 price target on shares of Aimmune Therapeutics in a research note on Wednesday, May 30th. BidaskClub raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $64.00 price target on shares of Aimmune Therapeutics in a research note on Wednesday, May 9th. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Friday, May 4th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Aimmune Therapeutics currently has an average rating of “Buy” and an average price target of $52.89.
In related news, insider Douglas T. Sheehy sold 3,296 shares of Aimmune Therapeutics stock in a transaction that occurred on Tuesday, May 22nd. The shares were sold at an average price of $33.00, for a total value of $108,768.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stephen George Dilly sold 29,457 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $30.83, for a total transaction of $908,159.31. Following the completion of the transaction, the chief executive officer now owns 344,765 shares of the company’s stock, valued at approximately $10,629,104.95. The disclosure for this sale can be found here. Insiders sold 364,493 shares of company stock valued at $11,580,119 in the last 90 days. Company insiders own 14.70% of the company’s stock.
Several hedge funds have recently made changes to their positions in AIMT. Wells Fargo & Company MN grew its holdings in shares of Aimmune Therapeutics by 3.1% in the fourth quarter. Wells Fargo & Company MN now owns 63,158 shares of the biotechnology company’s stock valued at $2,388,000 after purchasing an additional 1,892 shares in the last quarter. Raymond James & Associates grew its holdings in Aimmune Therapeutics by 7.2% during the 4th quarter. Raymond James & Associates now owns 24,737 shares of the biotechnology company’s stock worth $936,000 after acquiring an additional 1,669 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in Aimmune Therapeutics during the 4th quarter worth approximately $646,000. Alps Advisors Inc. grew its holdings in Aimmune Therapeutics by 34.7% during the 1st quarter. Alps Advisors Inc. now owns 75,900 shares of the biotechnology company’s stock worth $2,416,000 after acquiring an additional 19,538 shares in the last quarter. Finally, Wedbush Securities Inc. acquired a new position in Aimmune Therapeutics during the 1st quarter worth approximately $292,000. Hedge funds and other institutional investors own 80.16% of the company’s stock.
Shares of Aimmune Therapeutics stock traded up $0.07 on Friday, reaching $27.97. The company had a trading volume of 500,700 shares, compared to its average volume of 685,800. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -10.67 and a beta of -0.24. Aimmune Therapeutics has a 52-week low of $18.74 and a 52-week high of $42.00.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
See Also: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.